Antiepileptika-Therapie bei Einschränkung der Nierenfunktion

M. Hintz; A. Schulze-Bonhage

doi:10.1055/s-0035-1545309

Aktuelle Neurologie, Table of Contents

Aktuelle Neurologie 2015; 42(02): 86-92
DOI: 10.1055/s-0035-1545309

Übersicht

Antiepileptika-Therapie bei Einschränkung der Nierenfunktion

Antiepileptic Drug Therapy in Patients with Renal Failure

M. Hintz

¹Epilepsiezentrum, Universitätsklinikum Freiburg, Freiburg

,

A. Schulze-Bonhage

¹Epilepsiezentrum, Universitätsklinikum Freiburg, Freiburg

› Author Affiliations

Abstract

Zusammenfassung

Antiepileptika werden in unterschiedlichem Grade renal eliminiert. Zwischen AED der 1. und der 2. Generation bestehen wesentliche Unterschiede hinsichtlich ihrer Verstoffwechslung. Diese Übersicht soll dazu dienen, pharmakokinetische Aspekte der Antiepileptikatherapie und ihre Relevanz zur Dosierungsanpassung bei Epilepsiepatienten mit Niereneinschränkungen zusammenzufassen. Insbesondere wird der Einfluss der Hämodialyse auf die Plasmaspiegel der AED einschließlich der entsprechenden Therapieoptionen im Hinblick auf Medikamentenwahl und - ersatz dargestellt. Diese Informationen können hilfreich sein, um Fluktuationen innerhalb der Wirksamkeit der Anfallskontrolle bei Patienten mit Niereneinschränkungen zu vermeiden.

Abstract

Antiepileptic drugs (AED) are renally eliminated to different degrees. There are important differences in the metabolism of first and second generation AEDs. The aim of this review is to provide a summary of the pharmacokinetics of AEDS and their relevance for dose adaptations in epilepsy patients with renal impairment. In particular, the effects of hemodialysis on AED plasma levels and options for therapeutic management with regard to drug selection and supplementation are discussed here. This information may serve to minimize fluctuations in the efficacy of seizure control in patients with renal impairment.

Schlüsselwörter

Epilepsie - Antiepileptika - Nierenerkrankung - Hämodialyse - Pharmakokinetik

Keywords

epilepsy - antiepileptic drug - renal impairment - hemodialysis - pharmakokinetics

Full Text

References

Literatur
1 Browne TR. Pharmacokinetics of antiepileptic drugs. Neurology 1998; 51: 2-7
2 Diaz A, Deliz B, Benbadis SR. The use of newer antiepileptic drugs in patients with renal failure. Expert Rev Neurother 2012; 12: 99-105
3 Beyenburg S, Bauer J. Neuere klinische Aspekte der neuen Antiepileptika. Z Epileptol 2004; 17: 30-41
4 Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol 2014; 119: 417-432
5 Chronische Niereninsuffizienz [02.11.2014]. Im Internet: http://www.urologielehrbuch.de/chronische_niereninsuffizienz.html
6 DGfN Das Nierenportal Dialyse [02.11.2014]. Im Internet: http://www.dgfn.eu/presse/downloadbereich/dialyse.html
7 Israni RK, Kasbekar N, Haynes K et al. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006; 19: 408-416
8 Schuerer DJE, Brophy PD, Maxvold NJ et al. High-efficiency dialysis for carbamazepine overdose. Clin Toxicol 2000; 38: 321-323
9 Kielstein JT, Schwarz A, Arnavaz A et al. High-flux hemodialysis – an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. Clin Nephrol 2002; 57: 484-486
10 Tapolyai M, Campbell M, Dailey K et al. Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning. Nephron 2002; 90: 213-215
11 Chetty M. Carbamazepine poisoning: treatment with haemodialysis. Nephrol Dial Transplant 2003; 18: 220-221
12 Lee CS, Wang LH, Marbury TC et al. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol 1980; 17: 429-438
13 Hegarty J, Picton M, Agarwal G et al. Carbamazepine-induced acute granulomatous interstitial nephritis. Clin Nephrol 2002; 57: 310-313
14 Eijgenraam JW, Buurke EJ, van der Laan JS. Carbamazepine-associated acute tubulointerstitial nephritis. Neth J Med 1997; 50: 25-28
15 De Bragança AC, Moyses ZP, Magaldi AJ. Carbamazepine can induce kidney water absorption by increasing aquaporin 2 expression. Nephrol Dial Transplant 2010; 25: 3840-3845
16 Van der Lubbe N, Thompson CJ, Zietse R et al. The clinical challenge of SIADH-three cases. NDT Plus 2009; 2: 20-24
17 Asconapé JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002; 22: 27-39
18 Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-175
19 Maramattom BV. Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures. Neurology 2006; 66: 773-774
20 Hyponatriämie unter Escitalopram UAW-News – International [02.11.2014]. Im Internet: http://www.akdae.de/Arzneimittelsicherheit/Bekanntgaben/Archiv/2006/774_20060217.html
21 Buchanan RA, Kinkel AW, Smith TC. The absorption and excretion of ethosuximide. Int J Clin Pharmacol 1973; 7: 213-218
22 Marbury TC, Lee CS, Perchalski RJ et al. Hemodialysis clearance of ethosuximide in patients with chronic renal disease. Am J Hosp Pharm 1981; 38: 1757-1760
23 Marquardt ED, Ishisaka DY, Batra KK et al. Removal of ethosuximide and phenobarbital by peritoneal dialysis in a child. Clin Pharm 1992; 11: 1030-1031
24 Casteels K, Van Geet C, Wouters K. Ethosuximide-associated lupus with cerebral and renal manifestations. Eur J Pediatr 1998; 157: 780
25 Takeda S, Koizumi F, Takazakura E. Ethosuximide-induced lupus-like syndrome with renal involvement. Intern Med Tokyo Jpn 1996; 35: 587-591
26 Zawada ET, Nappi J, Done G et al. Advances in the hemodialysis management of phenobarbital overdose. South Med J 1983; 76: 6-8
27 Palmer BF. Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose. Am J Kidney Dis 2000; 36: 640-643
28 Porto I, John EG, Heilliczer J. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child. Pharmacotherapy 1997; 17: 832-835
29 Odar-Cederlöf I, Lunde P, Sjöqvist F. Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet 1970; 296: 831-832
30 Reidenberg MM, Odar-Cederlöf I, von Bahr C et al. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 1971; 285: 264-267
31 Hooper WD, Bochner F, Eadie MJ et al. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 1974; 15: 276-282
32 Reidenberg MM, Drayer DE. Effects of renal disease upon drug disposition. Drug Metab Rev 1978; 8: 293-302
33 Vanholder R, Van Landschoot N, De Smet R et al. Drug protein binding in chronic renal failure: Evaluation of nine drugs. Kidney Int 1988; 33: 996-1004
34 Olsen GD, Bennett WM, Porter GA. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther 1975; 17: 677-684
35 Martin E. Removal of phenytoin by hemodialysis in uremic patients. JAMA 1977; 238: 1750
36 Frenchie D, Bastani B. Significant removal of phenytoin during high flux dialysis with cellulose triacetate dialyzer. Nephrol Dial Transplant 1998; 13: 817-818
37 Heipertz R, Guthoff A, Bernhardt W. Primidone metabolism in renal insufficiency and acute intoxication. J Neurol 1979; 221: 101-104
38 Lee C-SC, Marbury TC, Perchalski RT et al. Pharmacokinetics of primidone elimination by uremic patients. J Clin Pharmacol 1982; 22: 301-308
39 Lehmann DF. Primidone crystalluria following overdose. A report of a case and an analysis of the literature. Med Toxicol Adverse Drug Exp 1987; 2: 383-387
40 Bruni J, Wang LH, Marbury TC et al. Protein binding of valproic acid in uremic patients. Neurology 1980; 30: 557-559
41 Dasgupta A, Jacques M, Malhotra D. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds. Am J Nephrol 1996; 16: 327-333
42 Kandrotas RJ, Love JM, Gal P et al. The effect of hemodialysis and hemoperfusion on serum valproic acid concentration. Neurology 1990; 40: 1456-1458
43 Kane SL, Constantiner M, Staubus AE et al. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother 2000; 34: 1146-1151
44 Kielstein JT, Woywodt A, Schumann G et al. Efficiency of high-flux hemodialysis in the treatment of valproic acid intoxication. J Toxicol Clin Toxicol 2003; 41: 873-876
45 Yoshikawa H, Watanabe T, Abe T. Tubulo-interstitial nephritis caused by sodium valproate. Brain Dev 2002; 24: 102-105
46 Knorr M, Schaper J, Harjes M et al. Fanconi syndrome caused by antiepileptic therapy with valproic Acid. Epilepsia 2004; 45: 868-871
47 Branten AJ, Wetzels JF, Weber AM et al. Hyponatremia due to sodium valproate. Ann Neurol 1998; 43: 265-267
48 Schulze-Bonhage A. Epilepsien und ihre medikamentöse Behandlung. Med Monatsschrift Für Pharm 2010; 33: 207-214
49 Almeida L, Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R D 2003; 4: 269-284
50 Maia J, Almeida L, Falcão A et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J. Clin Pharmacol Ther 2008; 46: 119-130
51 Shumaker RC, Fantel C, Kelton E et al. Evaluation of the elimination of [14C] felbamate in healthy men. Epilepsia 1990; 31: 642
52 Leppik IE. Felbamate. Epilepsia 1995; 36: 66-72
53 Johannessen SI, Battino D, Berry DJ et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-363
54 Glue P, Sulowicz W, Colucci R et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol 1997; 44: 91-93
55 Vollmer KO, von Hodenberg A, Kölle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986; 36: 830-839
56 McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994; 44: 17-22 31–32
57 Blum RA, Comstock TJ, Sica DA et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994; 56: 154-159
58 Wong MO, Eldon MA, Keane WF et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995; 35: 622-626
59 Dougherty JA, Rhoney DH. Gabapentin: a unique anti-epileptic agent. Neurol Res 2001; 23: 821-829
60 Wootton R, Soul-Lawton J, Rolan PE et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997; 43: 23-27
61 Fillastre JP, Taburet AM, Fialaire A et al. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993; 19: 25-32
62 French J. Use of levetiracetam in special populations. Epilepsia 2001; 42: 40-43
63 Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001; 21: 1375-1388
64 Rouan MC, Lecaillon JB, Godbillon J et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47: 161-167
65 Randinitis EJ, Posvar EL, Alvey CW et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003; 43: 277-283
66 Hermann R, Ferron GM, Erb K et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003; 73: 61-70
67 Perucca E, Cloyd J, Critchley D. Rufinamide: Clinical pharmacokinetics and concentrationresponse relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-1141
68 Cato A, Gustavson LE, Qian J et al. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 1998; 39: 43-47
69 Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35: 241-256
70 Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19: 1294-1308
71 Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926
72 Ijiri Y, Inoue T, Fukuda F et al. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Epilepsia 2004; 45: 924-927
73 Kochak GM, Page JG, Buchanan RA et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998; 38: 166-171
74 Brandt C, May TW. Therapeutic drug monitoring of newer antiepileptic drugs/Therapeutic drug monitoring bei neueren Antiepileptika. Laboratoriums Medizin 2011; 35: 161-169